Acadia Pharmaceuticals (ACAD) Enterprise Value (2016 - 2025)
Historic Enterprise Value for Acadia Pharmaceuticals (ACAD) over the last 17 years, with Q3 2025 value amounting to -$847.0 million.
- Acadia Pharmaceuticals' Enterprise Value fell 4982.74% to -$847.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$847.0 million, marking a year-over-year decrease of 4982.74%. This contributed to the annual value of -$756.0 million for FY2024, which is 7226.09% down from last year.
- According to the latest figures from Q3 2025, Acadia Pharmaceuticals' Enterprise Value is -$847.0 million, which was down 4982.74% from -$762.0 million recorded in Q2 2025.
- In the past 5 years, Acadia Pharmaceuticals' Enterprise Value ranged from a high of -$345.9 million in Q3 2023 and a low of -$847.0 million during Q3 2025
- Moreover, its 5-year median value for Enterprise Value was -$500.9 million (2024), whereas its average is -$530.4 million.
- Its Enterprise Value has fluctuated over the past 5 years, first skyrocketed by 2281.04% in 2022, then plummeted by 7226.09% in 2024.
- Acadia Pharmaceuticals' Enterprise Value (Quarter) stood at -$520.7 million in 2021, then increased by 19.95% to -$416.8 million in 2022, then dropped by 5.29% to -$438.9 million in 2023, then tumbled by 72.26% to -$756.0 million in 2024, then decreased by 12.04% to -$847.0 million in 2025.
- Its Enterprise Value stands at -$847.0 million for Q3 2025, versus -$762.0 million for Q2 2025 and -$681.6 million for Q1 2025.